Navigation Links
New Rheumatoid Arthritis Treatment

A new study shows a novel new drug is beneficial for patients with rheumatoid arthritis. The drug targets T cells and is the first in a new class of drugs to be tested for rheumatoid arthritis. //

The drug is called cytotoxic T-lymphocyte-associated antigen 4-IgG1 or CTLA4Ig. Preliminary research shows CTLA4Ig may be effective for the treatment of rheumatoid arthritis. Researchers from Belgium conducted a study to see if this drug is helpful for patients with rheumatoid arthritis.

Rheumatoid arthritis is a disease that causes progressive joint damage and disability. For the study, researchers assigned patients to receive one of two doses of CTLA4Ig or placebo. All of the patients also received methotrexate therapy during the study. Researchers assessed the patients after six months using the criteria of the American College of Rheumatology (ACR). The ACR defines the response to the treatment according to its extent. A 20 percent clinical response rate is noted as ACR 20, 50 percent is ACR 50, and 70 percent is ACR 70. Researchers also looked at the patients’ quality of life.

Researchers report the patients treated with the higher dose of CTLA4Ig were more likely to have an ACR 20 than patients who received placebo. Higher rates of ACR 50 and ACR 70 were seen in both groups on the drug compared to placebo. The patients on the higher dose of the drug also saw improvements in eight measures of quality of life.

Study authors conclude the combination of CTLA4Ig and methotrexate improved the signs and symptoms of the disease, physical function, and quality of life in patients with rheumatoid arthritis. Researchers also say both doses of the drug were well tolerated by the patients. They say this study shows the value of this new class of drugs in the treatment of rheumatoid arthritis
'"/>




Page: 1

Related medicine news :

1. New treatment for Rheumatoid Arthritis
2. New Rheumatoid Arthritis Treatment
3. Consumption Of Red Meat Found To Double The Risk of Rheumatoid Arthritis
4. The Link Between Rheumatoid Arthritis And Heart Failure
5. Smoking during pregnancy increases risk of Rheumatoid Arthritis.
6. Good News For Those Of You Suffering From Rheumatoid Arthritis
7. Mineral Oil exposure increases risk of Rheumatoid Arthritis
8. Mineral Oil exposure increases risk of Rheumatoid Arthritis
9. Novel drug holds promise for treatment of Rheumatoid Arthritis
10. Study Offers Insights Into Treatment Of Rheumatoid Arthritis
11. Protein Linked To Accelerating Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent review ... as the number one company for hearing aids, ranking it higher ... other brands. ... Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, state-of-the-art, ...
Breaking Medicine Technology: